EUCTR2013-001150-10-GB进行中（未招募）1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 143
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patient = 18 years old
- •- Diagnosis of NMO or NMO spectrum disorder
- •- NMO-IgG seropositive
- •- Historical Relapse of at least 2 relapses in the last 12 months or 3 relapses in the last 24 months, with at least 1 relapse in the 12 months prior to the Screening
- •- EDSS score =7
- •- Immunosuppressive therapy is allowed provided patients have been on a stable maintenance dose prior to the Screening and remain on a stable dose for the duration of the study
- •- Patients must be willing and able to give written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 119
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •- Use of rituximab or mitoxantrone within 3 months prior to Screening
- •- Use of IVIg within 3 weeks prior to screening
研究者
相似试验
进行中（未招募）
1 期
Tocilizumab plus background therapy versus placebo plus background therapy in patients with severe COVID-19 pneumonia.Severe COVID-19 pneumoniaMedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001154-22-DKF. Hoffmann-La Roche Ltd450
进行中（未招募）
1 期
MP1032 Treatment in Patients with Moderate to Severe COVID-19Moderate to severe coronavirus disease 2019 (COVID 19)MedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 100000004862EUCTR2021-000344-21-ROMetrioPharm AG120
进行中（未招募）
1 期
MP1032 Treatment in Patients with Moderate to Severe COVID-19Moderate to severe coronavirus disease 2019 (COVID 19)MedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 100000004862EUCTR2021-000344-21-FRMetrioPharm AG132
进行中（未招募）
不适用
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)Focal EpilepsyMedDRA version: 14.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-019361-28-FICB BIOSCIENCES, INC.900
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPYPER-087-11OVARTIS BIOSCIENSES PERU S.A.,